UQ’s Molecular Clamp technology could help improve health outcomes for millions of people by enabling new vaccines against life-threatening respiratory viral infections
An AU$3.2 million prize has been awarded to AIBN researchers and industry partner Vaxxas, to develop and distribute an easy to use, next-generation COVID-19 mRNA vaccine on the company’s needle-free patch.
The AIBN has the knowledge and infrastructure to ensure Australia can develop and deliver clinical-grade vaccines whenever, and wherever, they are needed.
Developing new, cost effective technologies to remediate and protect remote sites and waterways that have been contaminated ‘forever chemicals’ (PFAS).
AIBN researchers have created world leading ‘quantum dot’ technology for electricity conversion to deliver significant upgrades on traditional solar cell technology.